Professionals from 53 countries convened at ISPOR’s first Global HTA Roundtable to share best practices and build consensus on global health technology assessment standards.
ISPOR—The Professional Society for Health Economics and Outcomes Research published the insights from its first Global Health Technology Assessment (HTA) Roundtable in an article in the March/April issue of Value & Outcomes Spotlight.
The society has a history of convening experts for regional HTA Roundtables across the globe. This was ISPOR’s first globally focused HTA Roundtable. The virtual ISPOR Global HTA Roundtable convened 100 HTA professionals from 53 countries worldwide in Q4 2024 to connect, share best practices, and build consensus on global HTA standards.
The roundtable participants focused on three key topics:
- gene therapies and other advanced therapy medicinal products,
- improving access to therapies while navigating budget constraints, and
- digital health with a focus on artificial intelligence (AI).
The participants’ consensus was that there is a strong need for greater international collaboration, transparency, and information sharing to address the common challenges HTA bodies face. The discussions also underscored the importance of adapting HTA methodologies to assess emerging technologies/advanced therapy medicinal products; digital health (including AI); and access to treatments.
ISPOR will be holding its next Global HTA Roundtable in 2026 in response to the experts’ strong agreement that more cross-regional collaboration and information sharing are greatly needed.
“ISPOR is committed to supporting events like the Global HTA Roundtable to foster collaboration, consensus, and the evolution of HTA methodologies,” says ISPOR CEO and executive director Rob Abbott in a release. “ISPOR’s Global HTA Roundtable ties directly to two objectives in the society’s new Strategic Plan 2030, including proactively horizon scanning to establish high-leverage health policy opportunities that the Society can contribute toward. It also engages broadly with stakeholders to increase the visibility and influence of health economics and outcomes research, which is vital to HTA.”
